$IFRX

Analysts initiated coverage on five companies: GE Vernova (GEV) with a Sell rating and $470 target, Inflarx (IFRX) with a Buy and $8 target, Lyntris (LYNX) with a Buy and $21 target, Freshworks (FRSH) with an Overweight and $18 target, and NET Power (NPWR) with an Outperform and $2.75 target. GEV closed at $957.27, IFRX at $2.09, LYNX at $12.74, FRSH at $11.89, and NPWR at $1.91 on Friday.

InflaRx N.V. (IFRX) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones • Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned • Initiated feasibility ass

iFOREX Financial Trading Holdings (LSE:IFRX) said shareholders approved at its 18 June 2026 AGM a final dividend of $0.055 per ordinary share for the year ended 31 Dec 2025. Ex-dividend date is 25 June 2026, record date 26 June 2026, and payment date 24 July 2026.

TCG Crossover III entities and Chen Yu have disclosed a shared beneficial ownership of 14,500,000 Ordinary Shares in InflaRx N.V. (IFRX), representing 9.8% of the company's outstanding shares. This passive investment was reported via a SCHEDULE 13G SEC filing, indicating that the entities do not intend to influence control of the issuer. The shares outstanding figure of 147,292,859 was based on an underwritten offering concluded on May 7, 2026.

InflaRx N.V. has successfully closed an underwritten public offering, raising $150 million through the sale of 11,538,460 ordinary shares at a price of $13.00 per share. This includes the full exercise of the underwriters' option to purchase additional shares. The net proceeds are intended to fund the company's ongoing clinical trials, preclinical development, and general corporate purposes.

InflaRx NV (IFRX) is projected to report a loss of 14 cents per share. This information comes from a Refinitiv earnings preview.

InflaRx (IFRX) reported new preclinical data indicating that its oral C5aR1 inhibitor, izicopan, generates low levels of reactive metabolites compared to the marketed C5aR1 inhibitor avacopan. In head-to-head in vitro studies using human liver microsomes, izicopan's conjugate levels remained significantly lower, suggesting reduced bioactivation. These findings, alongside previous Phase 1 and 2a data, support izicopan's differentiated profile and potential for improved safety.

InflaRx announced new preclinical data for its investigational C5aR1 inhibitor, izicopan, showing minimal reactive metabolite formation, suggesting a low bioactivation-related safety risk. This data, combined with prior clinical findings, supports izicopan's potential as a best-in-class C5aR inhibitor, offering a differentiated safety profile compared to existing treatments like avacopan. These findings aim to strengthen InflaRx's competitive position in complement-targeted therapies.

InflaRx N.V. (Nasdaq: IFRX) has announced that it will publish its financial and operating results for the first quarter of 2026 on May 7, 2026, before the market opens. The company, which focuses on pioneering anti-inflammatory therapeutics, will not be holding a conference call for this report. InflaRx highlights its lead program, izicopan, and previously developed vilobelimab, both targeting the complement system.

InflaRx, a Nasdaq-listed biopharmaceutical company, has regained compliance with the Nasdaq minimum bid price requirement. The company's shares traded at or above $1.00 for ten consecutive business days, resolving a prior delisting threat. This achievement stabilizes InflaRx's market standing and ensures continued access to capital markets for its promising anti-inflammatory drug candidates.